Tissue | Expression Dynamics | Abbreviation |
Colorectum (GSE201348) | | FAP: Familial adenomatous polyposis |
CRC: Colorectal cancer |
Colorectum (HTA11) | | AD: Adenomas |
SER: Sessile serrated lesions |
MSI-H: Microsatellite-high colorectal cancer |
MSS: Microsatellite stable colorectal cancer |
Endometrium | | AEH: Atypical endometrial hyperplasia |
EEC: Endometrioid Cancer |
Esophagus | | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Liver | | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Lung | | AAH: Atypical adenomatous hyperplasia |
AIS: Adenocarcinoma in situ |
IAC: Invasive lung adenocarcinoma |
MIA: Minimally invasive adenocarcinoma |
Oral Cavity | | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Prostate | | BPH: Benign Prostatic Hyperplasia |
Skin | | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
Thyroid | | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00108836 | Esophagus | ESCC | regulation of lipid storage | 36/8552 | 57/18723 | 5.87e-03 | 2.17e-02 | 36 |
GO:0009110 | Esophagus | ESCC | vitamin biosynthetic process | 15/8552 | 20/18723 | 7.60e-03 | 2.71e-02 | 15 |
GO:0006024 | Esophagus | ESCC | glycosaminoglycan biosynthetic process | 45/8552 | 75/18723 | 8.75e-03 | 3.08e-02 | 45 |
GO:007122215 | Esophagus | ESCC | cellular response to lipopolysaccharide | 113/8552 | 209/18723 | 8.79e-03 | 3.10e-02 | 113 |
GO:0006023 | Esophagus | ESCC | aminoglycan biosynthetic process | 47/8552 | 79/18723 | 9.29e-03 | 3.23e-02 | 47 |
GO:007121617 | Esophagus | ESCC | cellular response to biotic stimulus | 131/8552 | 246/18723 | 9.85e-03 | 3.39e-02 | 131 |
GO:00192168 | Esophagus | ESCC | regulation of lipid metabolic process | 172/8552 | 331/18723 | 1.20e-02 | 4.02e-02 | 172 |
GO:00713755 | Liver | NAFLD | cellular response to peptide hormone stimulus | 65/1882 | 290/18723 | 3.95e-10 | 9.62e-08 | 65 |
GO:00082023 | Liver | NAFLD | steroid metabolic process | 69/1882 | 319/18723 | 5.90e-10 | 1.28e-07 | 69 |
GO:19016536 | Liver | NAFLD | cellular response to peptide | 71/1882 | 359/18723 | 1.82e-08 | 2.09e-06 | 71 |
GO:00434346 | Liver | NAFLD | response to peptide hormone | 76/1882 | 414/18723 | 1.51e-07 | 1.09e-05 | 76 |
GO:00108765 | Liver | NAFLD | lipid localization | 79/1882 | 448/18723 | 4.75e-07 | 2.92e-05 | 79 |
GO:00620125 | Liver | NAFLD | regulation of small molecule metabolic process | 63/1882 | 334/18723 | 6.55e-07 | 3.79e-05 | 63 |
GO:00303013 | Liver | NAFLD | cholesterol transport | 30/1882 | 117/18723 | 1.08e-06 | 5.40e-05 | 30 |
GO:00072543 | Liver | NAFLD | JNK cascade | 38/1882 | 167/18723 | 1.12e-06 | 5.52e-05 | 38 |
GO:00068694 | Liver | NAFLD | lipid transport | 71/1882 | 398/18723 | 1.16e-06 | 5.59e-05 | 71 |
GO:00159183 | Liver | NAFLD | sterol transport | 32/1882 | 130/18723 | 1.27e-06 | 6.01e-05 | 32 |
GO:0016051 | Liver | NAFLD | carbohydrate biosynthetic process | 43/1882 | 202/18723 | 1.55e-06 | 6.96e-05 | 43 |
GO:00192163 | Liver | NAFLD | regulation of lipid metabolic process | 61/1882 | 331/18723 | 2.18e-06 | 9.24e-05 | 61 |
GO:00514036 | Liver | NAFLD | stress-activated MAPK cascade | 47/1882 | 239/18723 | 5.26e-06 | 1.93e-04 | 47 |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa05208 | Colorectum | AD | Chemical carcinogenesis - reactive oxygen species | 126/2092 | 223/8465 | 1.01e-24 | 1.68e-22 | 1.07e-22 | 126 |
hsa05415 | Colorectum | AD | Diabetic cardiomyopathy | 114/2092 | 203/8465 | 3.65e-22 | 3.06e-20 | 1.95e-20 | 114 |
hsa05010 | Colorectum | AD | Alzheimer disease | 174/2092 | 384/8465 | 1.82e-19 | 9.26e-18 | 5.91e-18 | 174 |
hsa04932 | Colorectum | AD | Non-alcoholic fatty liver disease | 90/2092 | 155/8465 | 4.83e-19 | 1.80e-17 | 1.15e-17 | 90 |
hsa05022 | Colorectum | AD | Pathways of neurodegeneration - multiple diseases | 201/2092 | 476/8465 | 4.54e-18 | 1.27e-16 | 8.09e-17 | 201 |
hsa05171 | Colorectum | AD | Coronavirus disease - COVID-19 | 113/2092 | 232/8465 | 9.90e-16 | 2.55e-14 | 1.63e-14 | 113 |
hsa05131 | Colorectum | AD | Shigellosis | 109/2092 | 247/8465 | 1.09e-11 | 2.44e-10 | 1.55e-10 | 109 |
hsa05132 | Colorectum | AD | Salmonella infection | 102/2092 | 249/8465 | 7.65e-09 | 1.28e-07 | 8.17e-08 | 102 |
hsa05130 | Colorectum | AD | Pathogenic Escherichia coli infection | 79/2092 | 197/8465 | 1.05e-06 | 1.36e-05 | 8.65e-06 | 79 |
hsa05135 | Colorectum | AD | Yersinia infection | 58/2092 | 137/8465 | 3.90e-06 | 4.35e-05 | 2.78e-05 | 58 |
hsa04066 | Colorectum | AD | HIF-1 signaling pathway | 48/2092 | 109/8465 | 7.25e-06 | 7.84e-05 | 5.00e-05 | 48 |
hsa04722 | Colorectum | AD | Neurotrophin signaling pathway | 50/2092 | 119/8465 | 2.28e-05 | 2.24e-04 | 1.43e-04 | 50 |
hsa05418 | Colorectum | AD | Fluid shear stress and atherosclerosis | 54/2092 | 139/8465 | 1.41e-04 | 1.16e-03 | 7.37e-04 | 54 |
hsa05417 | Colorectum | AD | Lipid and atherosclerosis | 73/2092 | 215/8465 | 1.31e-03 | 8.27e-03 | 5.27e-03 | 73 |
hsa05170 | Colorectum | AD | Human immunodeficiency virus 1 infection | 72/2092 | 212/8465 | 1.40e-03 | 8.46e-03 | 5.39e-03 | 72 |
hsa05220 | Colorectum | AD | Chronic myeloid leukemia | 31/2092 | 76/8465 | 1.41e-03 | 8.46e-03 | 5.39e-03 | 31 |
hsa05163 | Colorectum | AD | Human cytomegalovirus infection | 75/2092 | 225/8465 | 2.00e-03 | 1.10e-02 | 7.01e-03 | 75 |
hsa05160 | Colorectum | AD | Hepatitis C | 54/2092 | 157/8465 | 3.87e-03 | 1.96e-02 | 1.25e-02 | 54 |
hsa04071 | Colorectum | AD | Sphingolipid signaling pathway | 43/2092 | 121/8465 | 4.83e-03 | 2.28e-02 | 1.45e-02 | 43 |
hsa05166 | Colorectum | AD | Human T-cell leukemia virus 1 infection | 72/2092 | 222/8465 | 5.24e-03 | 2.44e-02 | 1.55e-02 | 72 |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
NFKB1 | SMC | Cervix | Healthy | SOD2,CXCL2,NFKB2, etc. | 8.36e-01 | |
NFKB1 | IMENT | Colorectum | MSS | TNFRSF6B,IRF1,C8orf4, etc. | 4.29e-02 | |
NFKB1 | AT2 | Lung | IAC | DENND4A,BACH1,KYNU, etc. | 1.83e-01 | |
NFKB1 | LC | Lung | IAC | SIPA1L1,AL078604.4,KYNU, etc. | 2.62e-01 | |
NFKB1 | M2MAC | Skin | Healthy | REL,ATP5F1E,SIPA1L1, etc. | 4.68e-01 | |
NFKB1 | M2MAC | Skin | SCCIS | REL,ATP5F1E,SIPA1L1, etc. | 2.92e-01 | |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
NFKB1 | SNV | Missense_Mutation | | c.1715C>T | p.Ser572Phe | p.S572F | P19838 | protein_coding | tolerated(0.64) | benign(0.201) | TCGA-A2-A0YH-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | adriamycin | SD |
NFKB1 | SNV | Missense_Mutation | novel | c.2191N>A | p.Gly731Arg | p.G731R | P19838 | protein_coding | deleterious(0) | probably_damaging(0.984) | TCGA-AR-A0TY-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unspecific | Paclitaxel | PD |
NFKB1 | SNV | Missense_Mutation | novel | c.119C>G | p.Ala40Gly | p.A40G | P19838 | protein_coding | tolerated(0.07) | possibly_damaging(0.854) | TCGA-AR-A0U0-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
NFKB1 | SNV | Missense_Mutation | novel | c.733N>A | p.Ala245Thr | p.A245T | P19838 | protein_coding | deleterious(0) | probably_damaging(0.942) | TCGA-AR-A24L-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | PD |
NFKB1 | SNV | Missense_Mutation | rs865962183 | c.574N>T | p.Arg192Trp | p.R192W | P19838 | protein_coding | deleterious(0.01) | probably_damaging(0.972) | TCGA-AR-A256-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | PD |
NFKB1 | SNV | Missense_Mutation | | c.221C>G | p.Ser74Cys | p.S74C | P19838 | protein_coding | deleterious(0) | probably_damaging(0.935) | TCGA-E2-A1LH-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD |
NFKB1 | SNV | Missense_Mutation | rs769204159 | c.1562N>T | p.Ala521Val | p.A521V | P19838 | protein_coding | tolerated(0.06) | probably_damaging(0.988) | TCGA-E2-A573-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | taxotere | CR |
NFKB1 | SNV | Missense_Mutation | novel | c.1308N>T | p.Met436Ile | p.M436I | P19838 | protein_coding | tolerated(0.25) | benign(0) | TCGA-HN-A2OB-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | fluorouracil | PD |
NFKB1 | insertion | Nonsense_Mutation | novel | c.2107_2108insTTCTAAATATCTACTAGGTATTTGATAAACGTGTGTTATTT | p.Gly703ValfsTer6 | p.G703Vfs*6 | P19838 | protein_coding | | | TCGA-A2-A04Q-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD |
NFKB1 | insertion | Frame_Shift_Ins | novel | c.1403_1404insGTTTTTTCCT | p.Asp469PhefsTer16 | p.D469Ffs*16 | P19838 | protein_coding | | | TCGA-AO-A03O-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | doxorubicin | SD |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
4790 | NFKB1 | KINASE, TRANSCRIPTION FACTOR, DRUGGABLE GENOME | | SJ000113257 | CHEMBL528694 | |
4790 | NFKB1 | KINASE, TRANSCRIPTION FACTOR, DRUGGABLE GENOME | | SANGUINARIUM | SANGUINARIUM | |
4790 | NFKB1 | KINASE, TRANSCRIPTION FACTOR, DRUGGABLE GENOME | | DYRENE | DYRENE | |
4790 | NFKB1 | KINASE, TRANSCRIPTION FACTOR, DRUGGABLE GENOME | | ISORHAMNETIN | ISORHAMNETIN | 25190466 |
4790 | NFKB1 | KINASE, TRANSCRIPTION FACTOR, DRUGGABLE GENOME | | MITOXANTRONE | MITOXANTRONE | |
4790 | NFKB1 | KINASE, TRANSCRIPTION FACTOR, DRUGGABLE GENOME | | PARTHENOLIDE | PARTHENOLIDE | 25190466 |
4790 | NFKB1 | KINASE, TRANSCRIPTION FACTOR, DRUGGABLE GENOME | | THALIDOMIDE | THALIDOMIDE | |
4790 | NFKB1 | KINASE, TRANSCRIPTION FACTOR, DRUGGABLE GENOME | | (S)-NOMIFENSINE | CHEMBL51697 | |
4790 | NFKB1 | KINASE, TRANSCRIPTION FACTOR, DRUGGABLE GENOME | | 6-CHLOROMELATONIN | CHEMBL34730 | |
4790 | NFKB1 | KINASE, TRANSCRIPTION FACTOR, DRUGGABLE GENOME | | TOSYL-L-LYSINE CHLOROMETHYL KETONE | CHEMBL466465 | |